Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > VEGF R2

VEGF R2

Brief Information

Name:Vascular endothelial growth factor receptor 2
Target Synonym:EC:2.7.10.1,EC 2.7.10,VEGFR2,KDR,Vascular endothelial growth factor receptor 2,Fetal liver kinase 1,Kinase insert domain receptor,Kinase Insert Domain Receptor (A Type III Receptor Tyrosine Kinase),Protein-Tyrosine Kinase Receptor Flk-1,FLK1,Tyrosine Kinase Growth Factor Receptor,Fetal Liver Kinase-1,Soluble VEGFR2,CD309 Antigen,EC 2.7.10.1,VEGFR-2,CD309,VEGFR,FLK-1,Vascular Endothelial Growth Factor Receptor-2
Number of Launched Drugs:16
Number of Drugs in Clinical Trials:47
Lastest Research Phase:Approved

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

VE2-HA224-Cell-based assay
 VEGF R2 FACS

5e5 of anti-VEGF R2 CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of APC-Labeled Human VEGF R2 Protein, His Tag (Cat. No. VE2-HA224) and negative control protein respectively. APC signal was used to evaluate the binding activity (QC tested).

KDR-HP227-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

5e5 of anti-VEGFR2 CAR-293 cells were stained with 100 μL of 1:25 dilution (4 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human VEGF R2, His Tag (Cat. No. KDR-HP227) and negative control protein respectively. PE signal was used to evaluate the binding activity (QC tested).

VE2-M5258-BLI
 VEGF R2 BLI

Loaded Biotinylated Mouse VEGF164, His,Avitag (Cat. No. VE4-M82Q3) on SA Biosensor, can bind Mouse VEGF R2 Protein, Mouse IgG2a Fc Tag (Cat. No. VE2-M5258) with an affinity constant of 1.33 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

KDR-H82E5-BLI
 VEGF R2 BLI

Loaded Biotinylated Human VEGF R2, Avitag,His Tag (Cat. No. KDR-H82E5) on SA Biosensor, can bind Human VEGF-D, His Tag (Cat. No. VED-H5228) with an affinity constant of 482 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Synonym Name

KDR,CD309,FLK1,VEGFR,VEGFR2

Background

Kinase insert domain receptor (KDR) is also known as CD309, FLK1, VEGFR, VEGFR2, and  is one of the subtypes of VEGFR. VEGF receptors are receptors for vascular endothelial growth factor (VEGF). There are three main subtypes of VEGFR, numbered 1, 2 and 3. The VEGF receptors have an extracellular portion consisting of 7 immunoglobulin-like domains, a single transmembrane spanning region and an intracellular portion containing a split tyrosine-kinase domain. VEGF-A binds to VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1). VEGFR-2 appears to mediate almost all of the known cellular responses to VEGF.The function of VEGFR-1 is less well defined, although it is thought to modulate VEGFR-2 signaling. Another function of VEGFR-1 may be to act as a dummy/decoy receptor, sequestering VEGF from VEGFR-2 binding (this appears to be particularly important during vasculogenesis in the embryo). In addition, VEGFR2 is able to interact with HIV-1 extracellular Tat protein upon VEGF activation, and seems to enhance angiogenesis in Kaposi's sarcoma lesions.

Clinical and Translational Updates

Related Molecule

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Midostaurin PKC-412; PKC-412A; CGP-41231; CGP-41251 Approved Novartis Pharma Ag Rydapt United States Leukemia, Myeloid, Acute; Mastocytosis Novartis Europharm Ltd 2017-04-28 Hematologic Neoplasms; Leukemia; Mastocytosis, Systemic; Myelodysplastic Syndromes; Leukemia, Mast-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Hepatic Insufficiency; Leukemia, Myeloid, Acute; Mastocytosis Details
Apatinib Mesylate YN-968D1 Approved Advenchen Laboratories Llc 艾坦, Aitan Mainland China Stomach Neoplasms Jiangsu shengdi Medicine Co Ltd 2014-10-17 Carcinoma, Adenoid Cystic; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Carcinoma, Hepatocellular; Glioma; Fallopian Tube Neoplasms; Lung Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Nasopharyngeal Carcinoma; Breast Neoplasms; Liver Diseases; Solid tumours; Neoplasms; Nasopharyngeal Neoplasms; Carcinoma, Ovarian Epithelial; Triple Negative Breast Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Liver Neoplasms; Biliary Tract Neoplasms; Head and Neck Neoplasms; Ovarian Neoplasms Details
Anlotinib Dihydrochloride AL-3818 Approved Advenchen Laboratories Llc, Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd 福可维 Mainland China Thyroid Neoplasms Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd 2018-05-08 Esophageal Squamous Cell Carcinoma; Bone Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Hepatic Insufficiency; Gastrointestinal Stromal Tumors; Urologic Neoplasms; Sarcoma, Alveolar Soft Part; Endometrial Neoplasms; Gallbladder Neoplasms; Bile Duct Diseases; Thyroid Neoplasms; Fallopian Tube Neoplasms; Lung Neoplasms; Glioma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Melanoma; Carcinoma, Hepatocellular; Osteoma; Small Cell Lung Carcinoma; Head and Neck Neoplasms; Solid tumours; Biliary Tract Neoplasms; Drug-Related Side Effects and Adverse Reactions; Ovarian Neoplasms; Esophageal Neoplasms; Thoracic Neoplasms; Carcinoma, Renal Cell; Stomach Neoplasms; Leiomyosarcoma; Lymphoma, Large B-Cell, Diffuse; Neoplasms; Carcinoma, Ovarian Epithelial; Sarcoma, Synovial; Neuroendocrine Tumors; Liver Diseases; Sarcoma; Medullary thyroid cancer (MTC); Nasopharyngeal Carcinoma Details
Vandetanib AZD-6474; CH-331; ZD-6474 Approved Astrazeneca Pharmaceutical Co Ltd Zactima, Caprelsa United States Medullary thyroid cancer (MTC) Astrazeneca Pharmaceutical Co Ltd 2011-04-06 Lymphoma; Prostatic Neoplasms; Urethral Neoplasms; Neuroblastoma; Colorectal Neoplasms; Gliosarcoma; Peritoneal Neoplasms; Ureteral Neoplasms; Bile Duct Neoplasms; Lymphoproliferative Disorders; Diffuse Intrinsic Pontine Glioma; Astrocytoma; Gastrointestinal Stromal Tumors; Lung Neoplasms; Thyroid Neoplasms; Pleural Effusion; Glioma; Carcinoma, Squamous Cell; Fallopian Tube Neoplasms; Gallbladder Neoplasms; Carcinoma, Neuroendocrine; Multiple Endocrine Neoplasia Type 2b; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Precancerous Conditions; Neoplasm Metastasis; Carcinoma, Hepatocellular; Paraganglioma; von Hippel-Lindau Disease; Anus Neoplasms; Biliary Tract Neoplasms; Ovarian Neoplasms; Head and Neck Neoplasms; Intestinal Neoplasms; Kidney Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Abdominal Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma; Rectal Neoplasms; Pheochromocytoma; Solid tumours; Pancreatic Neoplasms; Neoplasms; Glioblastoma; Carcinoma, Transitional Details
Axitinib AG-013736; CLS-AX; AG-13736; PF-01367866 Approved Pfizer Pharmaceuticals Ltd (China) Inlyta, 英立达 United States Carcinoma, Renal Cell Pfizer Europe Ma Eeig 2012-01-27 Lymphoma; Carcinoma, Adenoid Cystic; Breast Neoplasms; Cholangiocarcinoma; Prostatic Neoplasms; Sarcoma; Colorectal Neoplasms; Hepatic Insufficiency; Carcinoma, Pancreatic Ductal; Thyroid Neoplasms; Carcinoma, Ductal; Leukemia, Myeloid, Acute; Lung Neoplasms; Carcinoma, Hepatocellular; Paraganglioma; Carcinoma, Non-Small-Cell Lung; Melanoma; Adenocarcinoma; Macular Degeneration; Adrenal Cortex Neoplasms; Kidney Neoplasms; Carcinoid Tumor; Carcinoma, Renal Cell; Pheochromocytoma; Stomach Neoplasms; Carcinoma; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Solid tumours; Glioblastoma; Pancreatic Neoplasms; Skin Neoplasms; Myelodysplastic Syndromes; Nasopharyngeal Neoplasms; Prostatic Neoplasms, Castration-Resistant; Neuroendocrine Tumors; Mesothelioma Details
Sorafenib Tosylate NSC-724772; BAY-43-0006; BAY-43-9006; BAY-54-9085 Approved Onyx Pharmaceuticals Inc Nexavar, 多吉美 United States Thyroid Neoplasms Bayer AG 2005-12-01 Liver Neoplasms; Leukemia, Myeloid; Lymphoma, B-Cell, Marginal Zone; Rhabdomyosarcoma; Head and Neck Neoplasms; Leukemia, Myelogenous, Chronic; Fibromatosis, Aggressive; Leiomyosarcoma; Kidney Neoplasms; Leukemia, Erythroblastic, Acute; Solid tumours; Lymphoma, T-Cell, Peripheral; Ovarian Neoplasms; Recurrence; Carcinoma, Renal Cell; Esophageal Neoplasms; Vipoma; Rectal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Histiocytoma, Malignant Fibrous; Carcinoma, Islet Cell; Hemangiosarcoma; Carcinoid Tumor; Carcinoma; Insulinoma; Stomach Neoplasms; Neoplasms; Pancreatic Neoplasms; Multiple Endocrine Neoplasia Type 2a; Hypertension, Portal; Carcinoma, Transitional Cell; Carcinoma, Verrucous; Thyroid Carcinoma, Anaplastic; Myelodysplastic Syndromes; Glioblastoma; Carcinoma, Ovarian Epithelial; Leukemia, Myelomonocytic, Acute; Colonic Neoplasms; Lymphoma, Large B-Cell, Diffuse; Lymphomatoid Granulomatosis; Wilms Tumor; Leukemia, Myelomonocytic, Chronic; Lymphoma, Large-Cell, Immunoblastic; Salivary Gland Neop Details
Regorafenib DAST; BAY-73-4506 Approved Bayer AG Stivarga, Resihance United States Gastrointestinal Stromal Tumors Bayer Pharma Ag 2012-09-27 Leukemia, Myeloid, Acute; Sarcoma; Gastrinoma; Osteosarcoma; Sarcoma, Ewing; Colorectal Neoplasms; Peritoneal Neoplasms; Gastrointestinal Stromal Tumors; Bile Duct Neoplasms; Fallopian Tube Neoplasms; Esophageal adenocarcinoma; Adenoma; Thyroid Neoplasms; Lung Neoplasms; Thymoma; Carcinoma, Hepatocellular; Adenocarcinoma; Melanoma; Neoplasm Metastasis; Gastrointestinal Neoplasms; Somatostatinoma; Carcinoma, Islet Cell; Ovarian Neoplasms; Liver Neoplasms; Hemangiosarcoma; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Rectal Neoplasms; Carcinoid Tumor; Insulinoma; Solid tumours; Colonic Neoplasms; Neoplasms; Carcinoma, Ovarian Epithelial; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Glioblastoma; Carcinoma, Transitional Cell; Carcinoma, Adenoid Cystic; Glucagonoma Details
Nintedanib Esylate BIBF-1120 Approved C.H. Boehringer Sohn Ag & Co. Kg Ofev, Vargatef United States Idiopathic Pulmonary Fibrosis Boehringer Ingelheim Gmbh 2014-10-15 Gliosarcoma; Breast Neoplasms; Sarcoma; systemic sclerosis-associated interstitial lung disease; Adenocarcinoma, Clear Cell; Peritoneal Neoplasms; Colorectal Neoplasms; Astrocytoma; Hepatic Insufficiency; Genital Neoplasms, Female; Silicosis; Prostatic Neoplasms; Carcinoma, Squamous Cell; Appendiceal Neoplasms; Fallopian Tube Neoplasms; Leukemia, Myeloid, Acute; Uterine Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Colonic Neoplasms; Ovarian Neoplasms; Telangiectasia, Hereditary Hemorrhagic; Esophageal Neoplasms; Rejection of lung transplantation; Carcinoid Tumor; Endometrial Stromal Tumors; Carcinoma, Renal Cell; Radiation Pneumonitis; Neoplasms; Idiopathic Pulmonary Fibrosis; Solid tumours; Scleroderma, Systemic; Glioblastoma; Small Cell Lung Carcinoma; Mesothelioma; Neuroendocrine Tumors; Pulmonary Fibrosis; Lung Diseases, Interstitial; Multiple Myeloma; Asbestosis; Oligodendroglioma Details
Fruquintinib HMPL-013 Approved Hutchison Medipharma Ltd 爱优特, Elunate Mainland China Colorectal Neoplasms Hutchison Medipharma Ltd 2018-09-04 Colonic Neoplasms; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Hepatic Insufficiency; Colorectal Neoplasms; Breast Neoplasms; Sarcoma; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Solid tumours; Kidney Diseases; Neoplasms; Rectal Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Esophageal Neoplasms; Biliary Tract Neoplasms Details
Cabozantinib S-malate XL-184; BMS-907351 Approved Exelixis Inc Cometriq, Cabometyx United States Thyroid Neoplasms; Carcinoma, Neuroendocrine Exelixis Inc 2012-11-29 Sarcoma, Ewing; Thyroid Neoplasms; Thymus Neoplasms; Gliosarcoma; Colorectal Neoplasms; Peritoneal Neoplasms; Bile Duct Neoplasms; Hepatic Insufficiency; Astrocytoma; Breast Neoplasms; Lymphoma; Osteosarcoma; Carcinoma, Adenosquamous; Adenocarcinoma, Clear Cell; Sarcoma, Clear Cell; Medullary thyroid cancer (MTC); Cholangiocarcinoma; Prostatic Neoplasms; Neurofibroma, Plexiform; Urethral Neoplasms; Carcinoma, Neuroendocrine; Meningioma; Carcinoma, Non-Small-Cell Lung; Paraganglioma; Melanoma; Carcinoma, Endometrioid; Thyroid Cancer, Papillary; Adenocarcinoma; Neoplasms, Germ Cell and Embryonal; Carcinoma, Hepatocellular; Neuroblastoma; Glioma; Leukemia, Myeloid, Acute; Carcinoma, Squamous Cell; Endometrial Neoplasms; Lung Neoplasms; Sarcoma, Alveolar Soft Part; Uterine Neoplasms; Fallopian Tube Neoplasms; Carcinoid Tumor; Neurofibromatoses; Seminoma; Carcinoma, Transitional Cell; Glioblastoma; Rejection of liver transplantation; Carcinoma, Merkel Cell; Hepatoblastoma; Pain; Pheochromocytoma; Neoplasms; Carcin Details
Pazopanib Hydrochloride GSK-786034; GW-786034B; SB-786034; GW-786034 Approved Glaxosmithkline Plc, Novartis Pharma Ag 维全特, Armala, Votrient, Patorma United States Sarcoma; Carcinoma, Renal Cell Novartis Pharma Ag 2009-10-19 Peritoneal Neoplasms; Lymphoma; Uterine Neoplasms; Lung Neoplasms; Carcinoma, Small Cell; Thyroid Neoplasms; Gastrointestinal Stromal Tumors; Gliosarcoma; Carcinoma, Mucoepidermoid; Genital Neoplasms, Female; Uterine Cervical Diseases; Choriocarcinoma; Colorectal Neoplasms; Neuroblastoma; Osteosarcoma; Gastrinoma; Psoriasis; Brain Neoplasms; Urethral Neoplasms; Breast Neoplasms; Medullary thyroid cancer (MTC); von Hippel-Lindau Disease; Gastrointestinal Neoplasms; Carcinoma, Hepatocellular; Melanoma; Endodermal Sinus Tumor; Neoplasms, Germ Cell and Embryonal; Paraganglioma; Thyroid Cancer, Papillary; Neoplasm Metastasis; Uterine Cervical Neoplasms; Breast Neoplasms, Male; Prostatic Neoplasms; Macular Degeneration; Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms; Leukemia, Myeloid, Acute; Glioma; Germinoma; Carcinoma, Neuroendocrine; Carcinoma, Embryonal; Carcinoma, Squamous Cell; Telangiectasia, Hereditary Hemorrhagic; Thyroid Carcinoma, Anaplastic; Neoplasms; Hemangiosarcoma; Carcinoid Tumor; Herpes Details
Ramucirumab IMC-1121; IMC-1C11; LY-3009806; IMC-1121-B; BLA-125477 Approved Dyax Pharma Cyramza United States Gastrointestinal Stromal Tumors Eli Lilly And Company 2014-04-21 Breast Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Adenocarcinoma; Fallopian Tube Neoplasms; Gallbladder Neoplasms; Ureteral Neoplasms; Urologic Neoplasms; Gastrointestinal Stromal Tumors; Peritoneal Neoplasms; Colorectal Neoplasms; Prostatic Neoplasms; Urethral Neoplasms; Ovarian Neoplasms; Cholangiocarcinoma; Klatskin Tumor; Carcinoma, Transitional Cell; Colonic Neoplasms; Pancreatic Neoplasms; Neoplasms; Carcinoma, Renal Cell; Rectal Neoplasms; Carcinoid Tumor; Esophageal Neoplasms; Stomach Neoplasms; Solid tumours; Liver Neoplasms Details
Tivozanib AV-951; KRN-951; ASP-4130; Kil-8951 Approved Kyowa Hakko Kirin Co Ltd Fotivda EU Carcinoma, Renal Cell Eusa Pharma (Netherlands) Bv 2017-08-24 Cholangiocarcinoma; Gastrointestinal Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Metastatic breast cancer; Fallopian Tube Neoplasms; Bile Duct Neoplasms; Peritoneal Neoplasms; Hepatic Insufficiency; Colorectal Neoplasms; Liver Neoplasms; Sarcoma; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Triple Negative Breast Neoplasms; Carcinoma, Renal Cell; Biliary Tract Neoplasms; Solid tumours; Ovarian Neoplasms Details
Lenvatinib Mesylate ER-203492-00; E-7080; MK-7902 Approved Eisai Co Ltd Kisplyx, Lenvima, Lenvima/Kisplyx, 乐卫玛 United States Thyroid Neoplasms Eisai Inc 2015-02-13 Liver Diseases; Paraganglioma; Neoplasm Metastasis; Thyroid Cancer, Papillary; Melanoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Glioma; Lymphoma; Endometrial Neoplasms; Thyroid Neoplasms; Hepatic Insufficiency; Osteosarcoma; Cholangiocarcinoma; Breast Neoplasms; Solid tumours; Neuroendocrine Tumors; Carcinoma, Adenoid Cystic; Adenocarcinoma, Follicular; Kidney Diseases; Neoplasms; Adenocarcinoma of Lung; Thyroid Carcinoma, Anaplastic; Pheochromocytoma; Renal Insufficiency; Esophageal Neoplasms; Carcinoma, Renal Cell; Ovarian Neoplasms; Liver Neoplasms; Biliary Tract Neoplasms Details
Ripretinib DCC-2618 Approved Deciphera 擎乐, Qinlock United States Gastrointestinal Stromal Tumors Deciphera Pharmaceuticals Llc 2020-05-15 Mastocytosis, Systemic; Neoplasms; Gastrointestinal Stromal Tumors Details
Sunitinib Malate PHA-290940; SU-010398; SU-11248; PNU-290940AD; PHA-290940AD; GB-102; PNU-290940; SU-011248-L-malate salt Approved Pfizer Pharmaceuticals Ltd (China) 索坦, Sutent United States Carcinoma, Renal Cell; Gastrointestinal Stromal Tumors Cppi Cv 2006-01-26 Teratoma; Ovarian Neoplasms; Fibromatosis, Aggressive; Solid tumours; Intestinal Neoplasms; Kidney Neoplasms; Liver Neoplasms; Leiomyosarcoma; Fibrosarcoma; HIV Infections; Head and Neck Neoplasms; Lymphoma, B-Cell, Marginal Zone; Lymphoma, B-Cell; Leukemia, Myeloid, Accelerated Phase; Leukemia; Leukemia, Myelogenous, Chronic; Lymphoma, T-Cell, Peripheral; Ependymoma; Carcinoma, Renal Cell; Histiocytoma, Malignant Fibrous; Carcinoma; Hemangioblastoma; Carcinoma, Islet Cell; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Thoracic Neoplasms; Leukemia, Hairy Cell; Abdominal Neoplasms; Esophageal Neoplasms; Polycythemia Vera; Pelvic Neoplasms; Pheochromocytoma; Glioblastoma; Neurofibromatoses; Pancreatic Neoplasms; Pancreatic neuroendocrine tumors (pNET); Salivary Gland Neoplasms; Small Cell Lung Carcinoma; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Carcinoma, Ovarian Epithelial; Carcinoma, Papillary; Neoplasms; Immunoglobulin Ligh Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
KHK-4951 Phase 1 Clinical Kyowa Kirin Wet Macular Degeneration; Macular Degeneration Details
Kanitinib CX-1003 Phase 1 Clinical Beijing Konruns Pharmaceutical Co Ltd, Guangzhou Yingsheng Bio Technology Co Ltd Solid tumours Details
NP-01 (Shijiazhuang No.4 Pharmaceutical/Nanjing Nadingfei Medical Technology) NP-01 Phase 1 Clinical Shijiazhuang No 4 Pharmaceutical Co Ltd, Nanjing Nadingfei Pharmaceutical Technology Co Ltd Solid tumours; Liver Neoplasms; Stomach Neoplasms; Lung Neoplasms Details
VEGFR-1/2 peptide vaccine (Keio University) Phase 2 Clinical Keio University Neurofibromatoses; Brain Neoplasms; Glioma Details
QBH-196 QBH-196 Phase 1 Clinical Shenyang Pharmaceutical University Solid tumours; Stomach Neoplasms Details
Tafetinib Malate SIM-0702; SIM-1005; SIM-010603 Phase 1 Clinical Jiangsu Simcere Pharmaceutical Co Ltd, Nanjing Yoko Biomedical Co Ltd, Jilin Boda Pharmaceutical Co Ltd Neoplasms Details
JY-025 JY-025 Phase 3 Clinical Beijing Jingyitaixiang Technology Development Co Ltd, Beijing Eastern Biotech Co Ltd Solid tumours; Liver Neoplasms; Stomach Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Metatinib Trometamol BMS-817378; SIM-817378 Phase 1 Clinical Bristol-Myers Squibb Company Solid tumours; Liver Neoplasms; Stomach Neoplasms; Colorectal Neoplasms Details
Ramucirumab biosimilar (Sichuan Kelunbotai Biopharmaceutical) Phase 1 Clinical Sichuan Kelun Pharmaceutical Co Ltd Solid tumours; Stomach Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
PZ-1 PZ-1 Phase 1 Clinical Chongqing University Of Arts And Sciences Solid tumours Details
Gentuximab Phase 1 Clinical Genescience Pharmaceuticals Co Ltd Carcinoma, Non-Small-Cell Lung Details
Simmitinib hydrochloride SOMCL-15-290 Phase 1 Clinical Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Solid tumours Details
LMV-12(HE003) LMV-12(HE003) Phase 1 Clinical Nanchang Hongyi Technology Co Ltd Solid tumours Details
Ningetinib Tosylate CT-053-PTSA; CT-053 Phase 2 Clinical Hec Pharm Co Ltd Solid tumours; Intestinal Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Lung Neoplasms; Leukemia, Myeloid, Acute; Carcinoma, Non-Small-Cell Lung Details
Recombinant anti-VEGFR2 chimeric monoclonaly antibody (GeneScience) Phase 3 Clinical Changchun Genescience Pharmaceutical Co Ltd Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
VEGFR2 peptide vaccine (VAXIMM) VXM-01 Phase 2 Clinical Merck Serono Glioblastoma; Pancreatic Neoplasms; Colorectal Neoplasms Details
KDR2-2 Phase 2 Clinical Guangzhou Huiborui Biomedical Technology Co Ltd Glaucoma, Neovascular; Neovascularization, Pathologic; Corneal Neovascularization Details
CEP-11981 ESK-981; CEP-11981; SSR-106462; BOL-303213X Phase 2 Clinical Sanofi Neoplasms; Prostatic Neoplasms Details
Pulocimab AK-109 Phase 2 Clinical Kang Rong Dongfang (Guangdong) Pharmaceutical Co Ltd Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Adenocarcinoma Details
Recombinant human anti-VEGFR2 monoclonal antibody (Buchang Pharma) BC-001 Phase 1 Clinical Shandong Buchang Pharmaceuticals Co Ltd Solid tumours Details
Ramucirumab biosimilar (Henlius) HLX-12 Phase 1 Clinical Shanghai Henlius Biotech Inc Stomach Neoplasms; Esophageal Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
MSB-0254 MSB-0254 Phase 1 Clinical Mabspace Biomedicine (Suzhou) Co Ltd Solid tumours Details
Gersizangitide AXT-107 Phase 2 Clinical AsclepiX Therapeutics Inc Diabetic macular oedema; Macular Degeneration Details
FNX-006 FNX-006 Phase 1 Clinical Sichuan University, Chengdu Fannuoxi Biomedical Technology Co Ltd Triple Negative Breast Neoplasms; Melanoma Details
Sorafenib Tosylate/MG-K10 MG-D-1609 Phase 2 Clinical Metagone Biotech Inc Solid tumours Details
SYHA-1817 SYHA-1817 Phase 1 Clinical CSPC Pharmaceutical Group Ltd Biliary Tract Neoplasms; Stomach Neoplasms; Carcinoma, Squamous Cell Details
VEGFR2 peptide vaccine (Tokyo University) Phase 1 Clinical University Of Tokyo Pancreatic Neoplasms Details
AVI-3207 AVI-3207 Phase 1 Clinical Avixgen Macular Degeneration Details
Ilorasertib ABT-348; A-9686600; Abbott-968660 Phase 2 Clinical Abbvie Inc Solid tumours; Leukemia, Myelogenous, Chronic; Neoplasms; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute; Leukemia, Lymphocytic, Chronic, B-Cell Details
RA1115-B1 RA1115-B1 Phase 1 Clinical Wet Macular Degeneration; Macular Degeneration Details
Famitinib Malate SHR-1020 Phase 3 Clinical Jiangsu Hengrui Medicine Co Ltd Cholangiocarcinoma; Neoplasm Metastasis; Gastrointestinal Neoplasms; Adenocarcinoma; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Thyroid Neoplasms; Endometrial Neoplasms; Lung Neoplasms; Urologic Neoplasms; Genital Neoplasms, Female; Gastrointestinal Stromal Tumors; Colorectal Neoplasms; Ovarian Neoplasms; Nasopharyngeal Carcinoma; Breast Neoplasms; Carcinoma, Transitional Cell; Pancreatic neuroendocrine tumors (pNET); Nasopharyngeal Neoplasms; Idiopathic Pulmonary Fibrosis; Triple Negative Breast Neoplasms; Neoplasms; Carcinoma, Renal Cell; Solid tumours; Biliary Tract Neoplasms Details
Axitinib intravitreal implant (Ocular Therapeutix) OTX-TKI Phase 1 Clinical Ocular Therapeutix Inc Macular Degeneration; Diabetic Retinopathy Details
KC1036 KC1036; KC-1036 Phase 2 Clinical Beijing Konruns Pharmaceutical Co Ltd Solid tumours; Hematologic Neoplasms; Neoplasms; Digestive System Neoplasms; Thymus Neoplasms; Adenocarcinoma; Neoplasm Metastasis Details
Lucitanib AL-3810; CO-3810; S-80881 Phase 3 Clinical Advenchen Laboratories Nanjing Ltd Solid tumours; Stomach Neoplasms; Small Cell Lung Carcinoma; Breast Neoplasms; Nasopharyngeal Carcinoma; Genital Neoplasms, Female; Colorectal Neoplasms; Thymus Neoplasms; Carcinoma, Small Cell; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular Details
LM-061 LM-061 Phase 2 Clinical Shanghai Lixin Pharmaceutical Research and Development Co Ltd Solid tumours Details
Pamufetinib TAS-115 Phase 1 Clinical Taiho Pharmaceutical Co Ltd, Otsuka Pharmaceutical Co Ltd Neoplasms Details
Glesatinib MGCD-265; MG-90265X; 7Q29OXD98N; MG-90265H9; MG-90265gly; MG-90265 Phase 2 Clinical Mirati Therapeutics Inc Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Zanzalintinib XL-092 Phase 3 Clinical Exelixis Inc Solid tumours; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Transitional Cell; Neoplasms; Prostatic Neoplasms, Castration-Resistant; Breast Neoplasms; Prostatic Neoplasms; Colorectal Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung Details
Cediranib AZD2171; AZD-2171; NSC-732208 Phase 3 Clinical Astrazeneca Plc Ovarian Neoplasms; Solid tumours; Ependymoma; Biliary Tract Neoplasms; Liver Neoplasms; Head and Neck Neoplasms; Leukemia; Leiomyosarcoma; Solitary Fibrous Tumor, Pleural; Medulloblastoma; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, T-Cell, Peripheral; Cystadenocarcinoma, Serous; Carcinoma, Renal Cell; Rectal Neoplasms; Carcinoma; Stomach Neoplasms; Rhabdoid Tumor; Cystadenoma, Serous; Spinal Cord Neoplasms; Cystadenocarcinoma, Mucinous; Squamous Cell Carcinoma of Head and Neck; Leukemia, Hairy Cell; Glioblastoma; Triple Negative Breast Neoplasms; Colonic Neoplasms; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Neoplasms; Hodgkin Disease; Hypopharyngeal Neoplasms; Leukemia-Lymphoma, Adult T-Cell; Carcinoma, Transitional Cell; Carcinoma, Ovarian Epithelial; Myelodysplastic Syndromes; Lymphoma, Large B-Cell, Diffuse; Nasopharyngeal Neoplasms; Salivary Gland Neoplasms; Carcinoma, Verrucous; Lymphomatoid Granulomatosis; Lymphoma, Large-Cell, Immunoblastic; Oligodendroglioma; Ascites; Uveal mel Details
Sitravatinib MG-91516; MGCD-516; IND-155305; MG-516 Phase 3 Clinical Mirati Therapeutics Inc Breast Neoplasms; Gastrointestinal Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Lung Neoplasms; Esophageal Squamous Cell Carcinoma; Mouth Neoplasms; Carcinoma, Squamous Cell; Hepatic Insufficiency; Ureteral Neoplasms; Solid tumours; Liposarcoma; Lung Diseases; Uveal melanoma; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Neoplasms; Carcinoma; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Kidney Neoplasms; Biliary Tract Neoplasms Details
Olinvacimab SSS-23; TTAC-0001 Phase 2 Clinical Pharmabcine Neoplasms; Glioblastoma; Triple Negative Breast Neoplasms; Neoplasm Metastasis Details
Brivanib Alaninate ZL-2301; BMS-540215; BMS-582664 Phase 2 Clinical Bristol-Myers Squibb Company Carcinoma, Squamous Cell; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Carcinoma, Endometrioid; Adenocarcinoma; Endometrial Neoplasms; Liver Neoplasms; Colorectal Neoplasms; Sarcoma; Neoplasms; Carcinoma, Transitional Cell; Pancreatic Neoplasms; Carcinoma, Renal Cell; Rectal Neoplasms; Solid tumours Details
Telatinib EOC-315; BAY-57-9352 Phase 2 Clinical Bayer AG Solid tumours; Stomach Neoplasms Details
EDP317 ACTB-1003; EOC-317; EDP-317 Phase 1 Clinical Bayer AG, Act Biotech Inc Biliary Tract Neoplasms; Solid tumours; Stomach Neoplasms; Urinary Bladder Neoplasms; Breast Neoplasms Details
BR-55 BR-55; BR55 CEUS Phase 2 Clinical Sonus Pharmaceuticals Ltd Ovarian Neoplasms; Neoplasms; Contrast agents; Inflammation; Diagnostic agents Details
Derazantinib ARQ-087.2HCl; AQ-14741087; ARQ-087; BAL-087 Phase 2 Clinical Arqule Inc Solid tumours; Biliary Tract Neoplasms; Stomach Neoplasms; Carcinoma, Transitional Cell; Cholangiocarcinoma; Urogenital Neoplasms; Carcinoma, Hepatocellular Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message